Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024 16:01 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
August 08, 2024 07:30 ET
|
Xilio Therapeutics, Inc.
Initiated enrollment in Phase 2 clinical trial of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
June 13, 2024 16:05 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
May 14, 2024 07:30 ET
|
Xilio Therapeutics, Inc.
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
April 01, 2024 16:05 ET
|
Xilio Therapeutics, Inc.
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
March 28, 2024 07:05 ET
|
Xilio Therapeutics, Inc.
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and...
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
March 28, 2024 07:00 ET
|
Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
-- Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers -- FOSTER CITY, Calif....
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
February 28, 2024 16:01 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
January 31, 2024 16:01 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
January 08, 2024 07:30 ET
|
Xilio Therapeutics, Inc.
Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed to date ...